Loading...
Back to narrative

ADAP.Y: Leadership And Listing Changes Will Drive Future Upside Potential

ADAP.Y: Compliance Efforts Will Overcome Index Removal To Drive Recovery

ADAP.Y logo
ADAP.Y
AnalystConsensusTarget
Not Invested
Published 04 Apr 2025

Update shared on 16 Dec 2025

Previous
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
-94.1%
7D
-26.8%

Narrative Update on Adaptimmune Therapeutics

Analysts have modestly increased their price target on Adaptimmune Therapeutics by approximately 3 percent to about 1.50 dollars per share, citing slightly stronger expected revenue growth and a marginally lower future price to earnings multiple in their updated models.

What's in the News

  • Chief Financial Officer Chris Hill has been appointed Chief Executive Officer and Director, succeeding long serving executive Adrian Rawcliffe as part of a broader company restructuring, while temporarily retaining his CFO role (company announcement).
  • Adaptimmune filed a Form 15 with the U.S. Securities and Exchange Commission to voluntarily deregister its American Depositary Shares under the Securities Exchange Act of 1934 (SEC filing).
  • Adaptimmune was removed from the Nasdaq Composite Index following recent market and listing developments (index notification).
  • The company received an exception from the Nasdaq Hearings Panel and has until December 1, 2025 to regain compliance with the minimum 1.00 dollar bid price requirement or face delisting from the Nasdaq Capital Market (Nasdaq notice).

Valuation Changes

  • Fair Value Estimate remains unchanged at approximately 1.50 dollars per share, indicating no revision to the intrinsic value assessment.
  • Discount Rate is effectively unchanged, holding steady at around 13.46 percent, suggesting a consistent risk and cost of capital assumption.
  • Revenue Growth has risen slightly, with the projected rate increasing from about 44.82 percent to approximately 46.25 percent, reflecting a modestly more optimistic sales outlook.
  • Net Profit Margin is essentially unchanged, remaining at roughly 16.03 percent. This implies stable long term profitability expectations.
  • Future P/E has fallen modestly, from around 20.0x to approximately 19.4x. This points to a slightly lower valuation multiple applied to anticipated earnings.

Have other thoughts on Adaptimmune Therapeutics?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.